Ulotaront (SEP-363856), a novel investigational drug, by Sumitomo Pharma/Otsuka Pharmaceuticals, has shown promise as a potential alternative treatment method for schizophrenia, as it lessens the n...
Unlike traditional antipsychotic medications that block dopamine receptors, CVL-231 selectively modulates the M4 receptor in the brain and provides antipsychotic effects without the need for titration. CVL-231, a once-daily medication, with enhanced potential for treatment adherence, seeks to bypass gastrointes...
Find MoreKarXT, likely to receive the nod from the US FDA by late 2024, will significantly impact the market with the potential to reduce the positive, negative, and cognitive symptoms of schizophrenia. The long-term data is encouraging, signaling that KarXT is not associated with “burdensome side effects” the major imp...
Find MoreIn the landscape of schizophrenia treatment, there are significant gaps that affect patients' lives profoundly. From the foggy terrain of early detection, where symptoms blur the lines between schizophrenia and other mental health conditions, to the daunting landscape of treatment resistance and relapse, where stan...
Find MoreLYN-005’s once-weekly dosing regimen reduces the pill burden for individuals with schizophrenia and schizoaffective disorders compared to traditional daily medications such as Risperdal. A unique capsule design consisting of six polymeric arms connected to a flexible core, encapsulated in a folded star-shaped f...
Find MoreDespite the urgent need for novel treatments, drug development for cognitive impairment associated with schizophrenia has been challenging, due to limited understanding, high trial failures, and few potential targets in the treatment regime. Iclepertin (BI 425809), an investigational asset, is a GlyT1 inhibitor...
Find MoreBrilaroxazine, developed by Reviva Therapeutics, exhibits potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia. Brilaroxazine’s pharmacological profile sets it apart from traditional antipsychotics. Operating as a partial agonist at D2/3/4 and 5-HT1A/2A recept...
Find MoreGlioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous system (CNS). Despite advancements in diagnostic approaches and the development of new therapies, the prognosis for glioblastoma patients remains notably poor, with limited improvement observed. At AACR ...
Find MoreThe findings presented at the 2024 AACR conference revealed that among patients diagnosed with PIK3Ca-mutated MSS mCRC (n = 22), three patients attained a partial response (PR). Additionally, one more patient with PIK3Ca-mutated mCRC maintained stable disease (SD). The study successfully achieved its primary endpoi...
Find MoreMelanoma, a type of skin cancer, poses a significant health concern globally. Advanced and metastatic stages of melanoma present particularly formidable challenges, often necessitating innovative treatment approaches to address their aggressive nature and high mortality rates. Patients with ICI-resistant metasta...
Find MoreAn inflammatory disease of large intestine, Ulcerative Colitis (UC), is approached with therapies th.....
Find MoreHemophilia, a genetic bleeding disorder characterized by a clotting factor protein deficiency. Intak.....
Find MoreDry Age-related Macular Degeneration (Dry AMD), also called atrophic AMD, is the most common form of.....
Find MoreMedical device manufacturing and development is a high-capital demanding endeavor and therefore the .....
Find MoreDiabetic macular edema (DME) is an eye disease in which there is fluid buildup in the macula. Even t.....
Find MoreDiabetic retinopathy is an eye condition that leads to vision loss and blindness in people who have .....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.